RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

Abstract

RNA modifications are pivotal posttranscriptional gene expression regulators with profound functions in both physiological and pathological states, particularly during cancer initiation and progression. Within the complex tumor microenvironment (TME), these modifications orchestrate diverse mechanisms that significantly impact tumor growth, facilitate immune evasion, and drive therapeutic resistance. Recent advances have demonstrated their critical roles in shaping RNA metabolism and maintaining genome integrity, as well as modulating key stromal pathways such as immune responses, extracellular matrix remodeling, and vascular supply. Emerging evidence further suggests that RNA modifications dynamically regulate intercellular communication between tumor cells and surrounding stromal and immune cells within the TME. In this review, we provide a comprehensive overview of the mechanisms and functional roles of major RNA modifications, including adenosine, guanosine, and pseudouridine modifications. We discuss their regulatory roles in RNA metabolism and genome integrity, and examine their diverse functions within the TME, including immune regulation, tumor proliferation, extracellular matrix remodeling, and DNA damage response (DDR) pathways. Additionally, we highlight recent advances in therapeutic strategies targeting RNA-modifying enzyme and discuss their potential for improving cancer treatment. Collectively, targeting RNA modification represents a promising strategy for overcoming cancer resistance and improving clinical treatment outcomes.

Keywords

immune cells / RNA metabolism / RNA modifications / tumor microenvironment

References

[1] C. M. Wei, A. Gershowitz, and B. Moss, “Methylated Nucleotides Block 5′ Terminus of HeLa Cell Messenger RNA,” Cell 4, no. 4 (1975): 379–386.

[2] T. Wang, S. Kong, M. Tao, and S. Ju, “The Potential Role of RNA N6-Methyladenosine in Cancer Progression,” Molecular Cancer 19, no. 1 (2020): 88.

[3] M. Safra, A. Sas-Chen, R. Nir, et al., “The m1A Landscape on Cytosolic and Mitochondrial mRNA at Single-Base Resolution,” Nature 551, no. 7679 (2017): 251–255.

[4] L. Xu, X. Liu, N. Sheng, et al., “Three Distinct 3-Methylcytidine (m ³ C) Methyltransferases Modify tRNA and mRNA in Mice and Humans,” Journal of Biological Chemistry 292, no. 35 (2017): 14695–14703.

[5] S. Schwartz, D. A. Bernstein, M. R. Mumbach, et al., “Transcriptome-Wide Mapping Reveals Widespread Dynamic-Regulated Pseudouridylation of ncRNA and mRNA,” Cell 159, no. 1 (2014): 148–162.

[6] J. Yang, J. Xu, W. Wang, B. Zhang, X. Yu, and S. Shi, “Epigenetic Regulation in the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Targets,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 1–26.

[7] S. Lin and M. Kuang, “RNA Modification-Mediated mRNA Translation Regulation in Liver Cancer: Mechanisms and Clinical Perspectives,” Nature Reviews Gastroenterology & Hepatology 21, no. 4 (2024): 267–281.

[8] D. Wang, Y. Han, L. Peng, et al., “Crosstalk Between N6-Methyladenosine (m6A) Modification and Noncoding RNA in Tumor Microenvironment,” International Journal of Biological Sciences 19, no. 7 (2023): 2198–2219.

[9] S. Delaunay, M. Helm, and M. Frye, “RNA Modifications in Physiology and Disease: Towards Clinical Applications,” Nature Reviews Genetics 25, no. 2 (2024): 104–122.

[10] Q. Wu, X. Fu, G. Liu, X. He, Y. Li, and C. Ou, “N7-Methylguanosine Modification in Cancers: From Mechanisms to Therapeutic Potential,” Journal of Hematology & Oncology 18, no. 1 (2025): 12.

[11] N. M. Anderson and M. C. Simon, “The Tumor Microenvironment,” Current Biology 30, no. 16 (2020): R921–R925.

[12] S. Qin, J. Jiang, Y. Lu, et al., “Emerging Role of Tumor Cell Plasticity in Modifying Therapeutic Response,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 1–36.

[13] I. A. Roundtree, M. E. Evans, T. Pan, and C. He, “Dynamic RNA Modifications in Gene Expression Regulation,” Cell 169, no. 7 (2017): 1187–1200.

[14] R. Desrosiers, K. Friderici, and F. Rottman, “Identification of Methylated Nucleosides in Messenger RNA From Novikoff Hepatoma Cells,” PNAS 71, no. 10 (1974): 3971–3975.

[15] S. Lin, J. Choe, P. Du, R. Triboulet, and R. I. Gregory, “The M(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells,” Molecular Cell 62, no. 3 (2016): 335–345.

[16] B. E. Maden, “Identification of the Locations of the Methyl Groups in 18 S Ribosomal RNA From Xenopus laevis and Man,” Journal of Molecular Biology 189, no. 4 (1986): 681–699.

[17] C. R. Alarcon, H. Lee, H. Goodarzi, N. Halberg, and S. F. Tavazoie, “N6-Methyladenosine Marks Primary MicroRNAs for Processing,” Nature 519, no. 7544 (2015): 482–485.

[18] F. Fazi and A. Fatica, “Interplay Between N (6)-Methyladenosine (m(6)A) and Non-Coding RNAs in Cell Development and Cancer,” Frontiers in Cell and Developmental Biology 7 (2019): 116.

[19] S. Oerum, V. Meynier, M. Catala, and C. Tisne, “A Comprehensive Review of m6A/m6Am RNA Methyltransferase Structures,” Nucleic Acids Research 49, no. 13 (2021): 7239–7255.

[20] C. Jaafar and R. C. T. Aguiar, “Dynamic Multilayered Control of m6A RNA Demethylase Activity,” Proceedings of the National Academy of Sciences 121, no. 46 (2024): e2317847121.

[21] Y. Fu, D. Dominissini, G. Rechavi, and C. He, “Gene Expression Regulation Mediated Through Reversible m6A RNA Methylation,” Nature Reviews Genetics 15, no. 5 (2014): 293–306.

[22] X. Jiang, B. Liu, Z. Nie, et al., “The Role of m6A Modification in the Biological Functions and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 1–16.

[23] P. C. He and C. He, “m6A RNA Methylation: From Mechanisms to Therapeutic Potential,” EMBO Journal 40, no. 3 (2021): e105977.

[24] Z. Shi, X. Cao, Y. Ma, et al., “RNA Methyltransferase METTL16: From Molecular Mechanisms to Therapeutic Prospects in Cancers,” Cancer Letters 624 (2025): 217698.

[25] U. L. RajBhandary, A. Stuart, R. D. Faulkner, S. H. Chang, and H. G. Khorana, “Nucleotide Sequence Studies on Yeast Phenylalanine sRNA,” Cold Spring Harbor Symposia on Quantitative Biology 31 (1966): 425–434.

[26] C. Peifer, S. Sharma, P. Watzinger, S. Lamberth, P. Kotter, and K. D. Entian, “Yeast Rrp8p, a Novel Methyltransferase Responsible for m1A 645 Base Modification of 25S rRNA,” Nucleic Acids Research 41, no. 2 (2013): 1151–1163.

[27] X. Li, X. Xiong, K. Wang, et al., “Transcriptome-Wide Mapping Reveals Reversible and Dynamic N(1)-Methyladenosine Methylome,” Nature Chemical Biology 12, no. 5 (2016): 311–316.

[28] L. Shi, W. Chen, Z. Zhang, J. Chen, and M. Xue, “N1-Methyladenosine Profiling of Long Non-Coding RNA in Colorectal Cancer,” IUBMB Life 73, no. 10 (2021): 1235–1243.

[29] C. Zhang and G. Jia, “Reversible RNA Modification N1-Methyladenosine (m1A) in mRNA and tRNA,” Genomics, Proteomics & Bioinformatics 16, no. 3 (2018): 155–161.

[30] D. Dominissini, S. Nachtergaele, S. Moshitch-Moshkovitz, et al., “The Dynamic N(1)-Methyladenosine Methylome in Eukaryotic Messenger RNA,” Nature 530, no. 7591 (2016): 441–446.

[31] D. T. Dubin and R. H. Taylor, “The Methylation State of Poly A-Containing Messenger RNA From Cultured Hamster Cells,” Nucleic Acids Research 2, no. 10 (1975): 1653–1668.

[32] J. E. Squires, H. R. Patel, M. Nousch, et al., “Widespread Occurrence of 5-Methylcytosine in Human Coding and Non-Coding RNA,” Nucleic Acids Research 40, no. 11 (2012): 5023–5033.

[33] N. A. Gkatza, C. Castro, R. F. Harvey, et al., “Cytosine-5 RNA Methylation Links Protein Synthesis to Cell Metabolism,” PLoS Biology 17, no. 6 (2019): e3000297.

[34] Z. Sun, S. Xue, M. Zhang, et al., “Aberrant NSUN2-Mediated M(5)C Modification of H19 lncRNA Is Associated With Poor Differentiation of Hepatocellular Carcinoma,” Oncogene 39, no. 45 (2020): 6906–6919.

[35] U. Schumann, H. N. Zhang, T. Sibbritt, et al., “Multiple Links Between 5-Methylcytosine Content of mRNA and Translation,” BMC Biology 18, no. 1 (2020): 40.

[36] A. Gigova, S. Duggimpudi, T. Pollex, M. Schaefer, and M. Kos, “A Cluster of Methylations in the Domain IV of 25S rRNA Is Required for Ribosome Stability,” RNA 20, no. 10 (2014): 1632–1644.

[37] M. Schosserer, N. Minois, T. B. Angerer, et al., “Methylation of Ribosomal RNA by NSUN5 Is a Conserved Mechanism Modulating Organismal Lifespan,” Nature Communications 6 (2015): 6158.

[38] A. Hayrapetyan, H. Grosjean, and M. Helm, “Effect of a Quaternary Pentamine on RNA Stabilization and Enzymatic Methylation,” Biological Chemistry 390, no. 9 (2009): 851–861.

[39] Y. Motorin and M. Helm, “tRNA Stabilization by Modified Nucleotides,” Biochemistry 49, no. 24 (2010): 4934–4944.

[40] L. Fu, C. R. Guerrero, N. Zhong, et al., “Tet-Mediated Formation of 5-Hydroxymethylcytosine in RNA,” Journal of the American Chemical Society 136, no. 33 (2014): 11582–11585.

[41] R. Wu, C. Sun, X. Chen, et al., “NSUN5/TET2-Directed Chromatin-Associated RNA Modification of 5-Methylcytosine to 5-Hydroxymethylcytosine Governs Glioma Immune Evasion,” Proceedings of the National Academy of Sciences 121, no. 14 (2024): e2321611121.

[42] K. E. Bohnsack, N. Kleiber, N. Lemus-Diaz, and M. T. Bohnsack, “Roles and Dynamics of 3-Methylcytidine in Cellular RNAs,” Trends in Biochemical Sciences 47, no. 7 (2022): 596–608.

[43] P. Throll, L. G. Dolce, P. Rico-Lastres, et al., “Structural Basis of tRNA Recognition by the m3C RNA Methyltransferase METTL6 in Complex With SerRS Seryl-tRNA Synthetase,” Nature Structural & Molecular Biology 31, no. 10 (2024): 1614–1624.

[44] J. Cui, E. Sendinc, Q. Liu, S. Kim, J. Y. Fang, and R. I. Gregory, “m3C32 tRNA Modification Controls Serine Codon-Biased mRNA Translation, Cell Cycle, and DNA-Damage Response,” Nature Communications 15, no. 1 (2024): 5775.

[45] K. G. Murthy, P. Park, and J. L. Manley, “A Nuclear Micrococcal-Sensitive, ATP-Dependent Exoribonuclease Degrades Uncapped but Not Capped RNA Substrates,” Nucleic Acids Research 19, no. 10 (1991): 2685–2692.

[46] L. Pandolfini, I. Barbieri, A. J. Bannister, et al., “METTL1 Promotes Let-7 MicroRNA Processing via m7G Methylation,” Molecular Cell 74, no. 6 (2019): 1278–1290.e9.

[47] S. Lin, Q. Liu, V. S. Lelyveld, J. Choe, J. W. Szostak, and R. I. Gregory, “Mettl1/Wdr4-Mediated m7G tRNA Methylome Is Required for Normal mRNA Translation and Embryonic Stem Cell Self-Renewal and Differentiation,” Molecular Cell 71, no. 2 (2018): 244–255.e5.

[48] L. S. Zhang, C. Liu, H. Ma, et al., “Transcriptome-Wide Mapping of Internal N7-Methylguanosine Methylome in Mammalian mRNA,” Molecular Cell 74, no. 6 (2019): 1304–1316.e8.

[49] A. Alexandrov, M. R. Martzen, and E. M. Phizicky, “Two Proteins That Form a Complex Are Required for 7-Methylguanosine Modification of Yeast tRNA,” RNA 8, no. 10 (2002): 1253–1266.

[50] R. Shaheen, G. M. H. Abdel-Salam, M. P. Guy, et al., “Mutation in WDR4 Impairs tRNA m7G46 Methylation and Causes a Distinct Form of Microcephalic Primordial Dwarfism,” Genome Biology 16, no. 1 (2015): 210.

[51] S. Haag, J. Kretschmer, and M. T. Bohnsack, “WBSCR22/Merm1 Is Required for Late Nuclear Pre-Ribosomal RNA Processing and Mediates N7-Methylation of G1639 in Human 18S rRNA,” RNA 21, no. 2 (2015): 180–187.

[52] W. E. Cohn, “Pseudouridine, a Carbon-Carbon Linked Ribonucleoside in Ribonucleic Acids: Isolation, Structure, and Chemical Characteristics,” Journal of Biological Chemistry 235 (1960): 1488–1498.

[53] T. M. Carlile, M. F. Rojas-Duran, B. Zinshteyn, H. Shin, K. M. Bartoli, and W. V. Gilbert, “Pseudouridine Profiling Reveals Regulated mRNA Pseudouridylation in Yeast and Human Cells,” Nature 515, no. 7525 (2014): 143–146.

[54] J. Karijolich and Y. T. Yu, “Converting Nonsense Codons Into Sense Codons by Targeted Pseudouridylation,” Nature 474, no. 7351 (2011): 395–398.

[55] K. Jack, C. Bellodi, D. M. Landry, et al., “rRNA Pseudouridylation Defects Affect Ribosomal Ligand Binding and Translational Fidelity From Yeast to Human Cells,” Molecular Cell 44, no. 4 (2011): 660–666.

[56] M. Charette and M. W. Gray, “Pseudouridine in RNA: What, Where, How, and Why,” IUBMB Life 49, no. 5 (2000): 341–351.

[57] N. Guzzi, M. Cieśla, P. C. T. Ngoc, et al., “Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells,” Cell 173, no. 5 (2018): 1204–1216.e26.

[58] Y. Yang, P. J. Hsu, Y. S. Chen, and Y. G. Yang, “Dynamic Transcriptomic m6A Decoration: Writers, Erasers, Readers and Functions in RNA Metabolism,” Cell Research 28, no. 6 (2018): 616–624.

[59] X. Deng, Y. Qing, D. Horne, H. Huang, and J. Chen, “The Roles and Implications of RNA m6A Modification in Cancer,” Nature Reviews Clinical Oncology 20, no. 8 (2023): 507–526.

[60] H. D. Lipshitz, J. M. Claycomb, and C. A. Smibert, “Post-Transcriptional Regulation of Gene Expression,” Methods 126 (2017): 1–2.

[61] H. Shi, X. Wang, Z. Lu, et al., “YTHDF3 Facilitates Translation and Decay of N(6)-Methyladenosine-Modified RNA,” Cell Research 27, no. 3 (2017): 315–328.

[62] T. Sun, R. Wu, and L. Ming, “The Role of m6A RNA Methylation in Cancer,” Biomedicine & Pharmacotherapy 112 (2019): 108613.

[63] X. Li, X. Xiong, M. Zhang, et al., “Base-Resolution Mapping Reveals Distinct M(1)A Methylome in Nuclear- and Mitochondrial-Encoded Transcripts,” Molecular Cell 68, no. 5 (2017): 993–1005.e9.

[64] Y. Sun, H. Dai, X. Dai, et al., “m1A in CAG Repeat RNA Binds to TDP-43 and Induces Neurodegeneration,” Nature 623, no. 7987 (2023): 580–587.

[65] M. Alriquet, G. Calloni, A. Martinez-Limon, et al., “The Protective Role of m1A During Stress-Induced Granulation,” Journal of Molecular Cell Biology 12, no. 11 (2021): 870–880.

[66] Q. Li, J. Liu, L. Guo, et al., “Decoding the Interplay Between m6A Modification and Stress Granule Stability by Live-Cell Imaging,” Science Advances 10, no. 46 (2024): eadp5689.

[67] A. Khong, T. Matheny, T. N. Huynh, V. Babl, and R. Parker, “Limited Effects of m6A Modification on mRNA Partitioning Into Stress Granules,” Nature Communications 13, no. 1 (2022): 3735.

[68] R. J. Ries, B. F. Pickering, H. X. Poh, S. Namkoong, and S. R. Jaffrey, “m6A Governs Length-Dependent Enrichment of mRNAs in Stress Granules,” Nature Structural & Molecular Biology 30, no. 10 (2023): 1525–1535.

[69] J. Park, Y. Wu, W. Shao, et al., “Poly(GR) Interacts With Key Stress Granule Factors Promoting Its Assembly Into Cytoplasmic Inclusions,” Cell Reports 42, no. 8 (2023): 112822.

[70] X. Dai, T. Wang, G. Gonzalez, and Y. Wang, “Identification of YTH Domain-Containing Proteins as the Readers for N1-Methyladenosine in RNA,” Analytical Chemistry 90, no. 11 (2018): 6380–6384.

[71] W. Miao, D. F. Porter, Y. Li, et al., “Glucose Binds and Activates NSUN2 to Promote Translation and Epidermal Differentiation,” Nucleic Acids Research 52, no. 22 (2024): 13577–13593.

[72] J. Liu, T. Huang, W. Chen, et al., “Developmental mRNA m5C Landscape and Regulatory Innovations of Massive m5C Modification of Maternal mRNAs in Animals,” Nature Communications 13, no. 1 (2022): 2484.

[73] H. Tang, X. Fan, J. Xing, et al., “NSun2 Delays Replicative Senescence by Repressing p27 (KIP1) Translation and Elevating CDK1 Translation,” Aging 7, no. 12 (2015): 1143–1158.

[74] Q. Li, X. Li, H. Tang, et al., “NSUN2-Mediated m5C Methylation and METTL3/METTL14-Mediated m6A Methylation Cooperatively Enhance p21 Translation,” Journal of Cellular Biochemistry 118, no. 9 (2017): 2587–2598.

[75] T. P. Hoernes, N. Clementi, K. Faserl, et al., “Nucleotide Modifications Within Bacterial Messenger RNAs Regulate Their Translation and Are Able to Rewire the Genetic Code,” Nucleic Acids Research 44, no. 2 (2016): 852–862.

[76] Y. Luo, J. Feng, Q. Xu, W. Wang, and X. Wang, “NSun2 Deficiency Protects Endothelium From Inflammation via mRNA Methylation of ICAM-1,” Circulation Research 118, no. 6 (2016): 944–956.

[77] X. Yang, Y. Yang, B. F. Sun, et al., “5-Methylcytosine Promotes mRNA Export—NSUN2 as the Methyltransferase and ALYREF as an M(5)C Reader,” Cell Research 27, no. 5 (2017): 606–625.

[78] M. Schaefer, T. Pollex, K. Hanna, et al., “RNA Methylation by Dnmt2 Protects Transfer RNAs Against Stress-Induced Cleavage,” Genes & Development 24, no. 15 (2010): 1590–1595.

[79] S. Blanco, S. Dietmann, J. V. Flores, et al., “Aberrant Methylation of tRNAs Links Cellular Stress to Neuro-Developmental Disorders,” EMBO Journal 33, no. 18 (2014): 2020–2039.

[80] H. Y. Zhang, J. Xiong, B. L. Qi, Y. Q. Feng, and B. F. Yuan, “The Existence of 5-Hydroxymethylcytosine and 5-Formylcytosine in Both DNA and RNA in Mammals,” Chemical Communications 52, no. 4 (2016): 737–740.

[81] B. Delatte, F. Wang, L. V. Ngoc, et al., “RNA Biochemistry. Transcriptome-Wide Distribution and Function of RNA Hydroxymethylcytosine,” Science 351, no. 6270 (2016): 282–285.

[82] M. H. Huang, G. X. Peng, X. L. Mao, et al., “Molecular Basis for Human Mitochondrial tRNA m3C Modification by Alternatively Spliced METTL8,” Nucleic Acids Research 50, no. 7 (2022): 4012–4028.

[83] E. Scholler, J. Marks, V. Marchand, et al., “Balancing of Mitochondrial Translation Through METTL8-Mediated M(3)C Modification of Mitochondrial tRNAs,” Molecular Cell 81, no. 23 (2021): 4810–4825.e12.

[84] F. Zhang, K. Yoon, D. Y. Zhang, N. S. Kim, G. L. Ming, and H. Song, “Epitranscriptomic Regulation of Cortical Neurogenesis via Mettl8-Dependent Mitochondrial tRNA m3C Modification,” Cell Stem Cell 30, no. 3 (2023): 300–311.e11.

[85] M. Olejniczak, T. Dale, R. P. Fahlman, and O. C. Uhlenbeck, “Idiosyncratic Tuning of tRNAs to Achieve Uniform Ribosome Binding,” Nature Structural & Molecular Biology 12, no. 9 (2005): 788–793.

[86] M. Olejniczak and O. C. Uhlenbeck, “tRNA Residues That Have Coevolved With Their Anticodon to Ensure Uniform and Accurate Codon Recognition,” Biochimie 88, no. 8 (2006): 943–950.

[87] N. Kleiber, N. Lemus-Diaz, C. Stiller, et al., “The RNA Methyltransferase METTL8 Installs M(3)C(32) in Mitochondrial tRNAs(Thr/Ser(UCN)) to Optimise tRNA Structure and Mitochondrial Translation,” Nature Communications 13, no. 1 (2022): 209.

[88] P. Auffinger and E. Westhof, “Singly and Bifurcated Hydrogen-Bonded Base-Pairs in tRNA Anticodon Hairpins and Ribozymes,” Journal of Molecular Biology 292, no. 3 (1999): 467–483.

[89] P. Auffinger and E. Westhof, “An Extended Structural Signature for the tRNA Anticodon Loop,” RNA 7, no. 3 (2001): 334–341.

[90] Q. Li, S. Jiang, K. Lei, et al., “Metabolic Rewiring During Bone Development Underlies tRNA M⁷G–Associated Primordial Dwarfism,” Journal of Clinical Investigation 134, no. 20 (2024): e177220.

[91] J. Ma, S. Zheng, C. An, et al., “Pathogenic Mechanism and Therapeutic Intervention of Impaired N7-Methylguanosine (m7G) tRNA Modification,” PNAS 121, no. 45 (2024): e2405886121.

[92] J. Li, L. Wang, Q. Hahn, et al., “Structural Basis of Regulated m7G tRNA Modification by METTL1-WDR4,” Nature 613, no. 7943 (2023): 391–397.

[93] A. Alexandrov, I. Chernyakov, W. Gu, et al., “Rapid tRNA Decay Can Result From Lack of Nonessential Modifications,” Molecular Cell 21, no. 1 (2006): 87–96.

[94] R. Xu, A. Du, X. Deng, et al., “tsRNA-GlyGCC Promotes Colorectal Cancer Progression and 5-FU Resistance by Regulating SPIB,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 230.

[95] A. Ramanathan, G. B. Robb, and S. H. Chan, “mRNA Capping: Biological Functions and Applications,” Nucleic Acids Research 44, no. 16 (2016): 7511–7526.

[96] Z. Zhao, Y. Qing, L. Dong, et al., “QKI Shuttles Internal M(7)G-Modified Transcripts Into Stress Granules and Modulates mRNA Metabolism,” Cell 186, no. 15 (2023): 3208–3226.e27.

[97] C. Liu, X. Dou, Y. Zhao, et al., “IGF2BP3 Promotes mRNA Degradation Through Internal m7G Modification,” Nature Communications 15, no. 1 (2024): 7421.

[98] W. V. Gilbert, “Recent Developments, Opportunities, and Challenges in the Study of mRNA Pseudouridylation,” RNA 30, no. 5 (2024): 530–536.

[99] C. Chen, X. Zhao, R. Kierzek, and Y. T. Yu, “A Flexible RNA Backbone Within the Polypyrimidine Tract Is Required for U2AF65 Binding and Pre-mRNA Splicing In Vivo,” Molecular and Cellular Biology 30, no. 17 (2010): 4108–4119.

[100] S. Schwartz, M. R. Mumbach, M. Jovanovic, et al., “Perturbation of m6A Writers Reveals Two Distinct Classes of mRNA Methylation at Internal and 5′ Sites,” Cell Reports 8, no. 1 (2014): 284–296.

[101] K. Kariko, H. Muramatsu, F. A. Welsh, et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Molecular Therapy 16, no. 11 (2008): 1833–1840.

[102] I. S. Fernandez, C. L. Ng, A. C. Kelley, G. Wu, Y. T. Yu, and V. Ramakrishnan, “Unusual Base Pairing During the Decoding of a Stop Codon by the Ribosome,” Nature 500, no. 7460 (2013): 107–110.

[103] H. Adachi, Y. Pan, X. He, et al., “Targeted Pseudouridylation: An Approach for Suppressing Nonsense Mutations in Disease Genes,” Molecular Cell 83, no. 4 (2023): 637–651.e9.

[104] V. Kalamara and G. A. Garinis, “The Epitranscriptome: Reshaping the DNA Damage Response,” Trends in Cell Biology 35, no. 4 (2025): 294–304.

[105] C. Zhang, L. Chen, D. Peng, et al., “METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation,” Molecular Cell 79, no. 3 (2020): 425–442.e7.

[106] X. Lu, L. Peng, J. Ding, et al., “A Deregulated m6A Writer Complex Axis Driven by BRD4 Confers an Epitranscriptomic Vulnerability in Combined DNA Repair–Targeted Therapy,” Proceedings of the National Academy of Sciences 120, no. 41 (2023): e2304534120.

[107] Y. Xiang, B. Laurent, C. H. Hsu, et al., “RNA M(6)A Methylation Regulates the Ultraviolet-Induced DNA Damage Response,” Nature 543, no. 7646 (2017): 573–576.

[108] D. Elvira-Blázquez, J. M. Fernández-Justel, and A. Arcas, “YTHDC1 m6A-Dependent and m6A-Independent Functions Converge to Preserve the DNA Damage Response,” EMBO Journal 43, no. 16 (2024): 3494–3522.

[109] Q. Zhang, R. C. Riddle, Q. Yang, et al., “The RNA Demethylase FTO Is Required for Maintenance of Bone Mass and Functions to Protect Osteoblasts From Genotoxic Damage,” PNAS 116, no. 36 (2019): 17980–17989.

[110] S. Deng, J. Zhang, J. Su, et al., “RNA m6A Regulates Transcription via DNA Demethylation and Chromatin Accessibility,” Nature Genetics 54, no. 9 (2022): 1427–1437.

[111] J. Wei, X. Yu, L. Yang, et al., “FTO Mediates LINE1 m6A Demethylation and Chromatin Regulation in mESCs and Mouse Development,” Science 376, no. 6596 (2022): 968–973.

[112] W. Xu, C. He, E. G. Kaye, et al., “Dynamic Control of Chromatin-Associated m6A Methylation Regulates Nascent RNA Synthesis,” Molecular Cell 82, no. 6 (2022): 1156–1168.e7.

[113] T. Sun, Y. Xu, Y. Xiang, J. Ou, E. J. Soderblom, and Y. Diao, “Crosstalk Between RNA m6A and DNA Methylation Regulates Transposable Element Chromatin Activation and Cell Fate in Human Pluripotent Stem Cells,” Nature Genetics 55, no. 8 (2023): 1324–1335.

[114] F. Yu, J. Wei, X. Cui, et al., “Post-Translational Modification of RNA m6A Demethylase ALKBH5 Regulates ROS-Induced DNA Damage Response,” Nucleic Acids Research 49, no. 10 (2021): 5779–5797.

[115] A. Svobodova Kovarikova, L. Stixova, and A. Kovarik, “N(6)-Adenosine Methylation in RNA and a Reduced M(3)G/TMG Level in Non-Coding RNAs Appear at Microirradiation-Induced DNA Lesions,” Cells 9, no. 2 (2020): 360.

[116] N. Raj, M. Wang, J. A. Seoane, et al., “The Mettl3 Epitranscriptomic Writer Amplifies p53 Stress Responses,” Molecular Cell 82, no. 13 (2022): 2370–2384.e10.

[117] J. Zhang, F. Chen, M. Tang, et al., “The ARID1A-METTL3-m6A Axis Ensures Effective RNase H1-Mediated Resolution of R-Loops and Genome Stability,” Cell Reports 43, no. 2 (2024): 113779.

[118] J. D. Hao, Q. L. Liu, M. X. Liu, et al., “DDX21 Mediates Co-Transcriptional RNA m6A Modification to Promote Transcription Termination and Genome Stability,” Molecular Cell 84, no. 9 (2024): 1711–1726.e11.

[119] X. Yang, Q. L. Liu, W. Xu, et al., “m(6)A Promotes R-Loop Formation to Facilitate Transcription Termination,” Cell Research 29, no. 12 (2019): 1035–1038.

[120] H. J. Kang, N. Y. Cheon, H. Park, et al., “TonEBP Recognizes R-Loops and Initiates m6A RNA Methylation for R-Loop Resolution,” Nucleic Acids Research 49, no. 1 (2021): 269–284.

[121] A. Abakir, T. C. Giles, A. Cristini, et al., “N6-Methyladenosine Regulates the Stability of RNA:DNA Hybrids in Human Cells,” Nature Genetics 52, no. 1 (2020): 48–55.

[122] H. Chen, H. Yang, X. Zhu, et al., “m(5)C Modification of mRNA Serves a DNA Damage Code to Promote Homologous Recombination,” Nature Communications 11, no. 1 (2020): 2834.

[123] H. Yang, Y. Wang, Y. Xiang, et al., “FMRP Promotes Transcription-Coupled Homologous Recombination via Facilitating TET1-Mediated m5C RNA Modification Demethylation,” PNAS 119, no. 12 (2022): e2116251119.

[124] L. H. Zhang, X. Y. Zhang, T. Hu, et al., “The SUMOylated METTL8 Induces R-Loop and Tumorigenesis via m3C,” iScience 23, no. 3 (2020): 100968.

[125] J. Liao, Y. Yi, X. Yue, et al., “Methyltransferase 1 Is Required for Nonhomologous End-Joining Repair and Renders Hepatocellular Carcinoma Resistant to Radiotherapy,” Hepatology 77, no. 6 (2023): 1896–1910.

[126] L. Bejarano, M. J. C. Jordāo, and J. A. Joyce, “Therapeutic Targeting of the Tumor Microenvironment,” Cancer Discovery 11, no. 4 (2021): 933–959.

[127] D. Han and M. M. Xu, “RNA Modification in the Immune System,” Annual Review of Immunology 41 (2023): 73–98.

[128] Q. Zheng, J. Hou, Y. Zhou, Z. Li, and X. Cao, “The RNA Helicase DDX46 Inhibits Innate Immunity by Entrapping M(6)A-Demethylated Antiviral Transcripts in the Nucleus,” Nature Immunology 18, no. 10 (2017): 1094–1103.

[129] Y. G. Chen, R. Chen, S. Ahmad, et al., “N6-Methyladenosine Modification Controls Circular RNA Immunity,” Molecular Cell 76, no. 1 (2019): 96–109.e9.

[130] O. R. Colegio, N. Q. Chu, A. L. Szabo, et al., “Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid,” Nature 513, no. 7519 (2014): 559–563.

[131] P. J. Murray, J. E. Allen, S. K. Biswas, et al., “Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines,” Immunity 41, no. 1 (2014): 14–20.

[132] L. Dong, C. Chen, Y. Zhang, et al., “The Loss of RNA N6-Adenosine Methyltransferase Mettl14 in Tumor-Associated Macrophages Promotes CD8+ T Cell Dysfunction and Tumor Growth,” Cancer Cell 39, no. 7 (2021): 945–957.e10.

[133] L. Wang, H. Hui, K. Agrawal, et al., “m(6)A RNA Methyltransferases METTL3/14 Regulate Immune Responses to Anti-PD-1 Therapy,” EMBO Journal 39, no. 20 (2020): e104514.

[134] H. Yin, X. Zhang, P. Yang, et al., “RNA m6A Methylation Orchestrates Cancer Growth and Metastasis via Macrophage Reprogramming,” Nature Communications 12, no. 1 (2021): 1394.

[135] J. Xiong, J. He, J. Zhu, et al., “Lactylation-Driven METTL3-Mediated RNA m6A Modification Promotes Immunosuppression of Tumor-Infiltrating Myeloid Cells,” Molecular Cell 82, no. 9 (2022): 1660–1677.e10.

[136] C. R. Alarcón, H. Goodarzi, H. Lee, X. Liu, S. Tavazoie, and S. F. Tavazoie, “HNRNPA2B1 Is a Mediator of m6A-Dependent Nuclear RNA Processing Events,” Cell 162, no. 6 (2015): 1299–1308..

[137] C. Villarroya-Beltri, C. Gutiérrez-Vázquez, F. Sánchez-Cabo, et al., “Sumoylated hnRNPA2B1 Controls the Sorting of miRNAs Into Exosomes Through Binding to Specific Motifs,” Nature Communications 4, no. 1 (2013): 2980.

[138] Z. Pan, R. Zhao, B. Li, et al., “EWSR1-Induced circNEIL3 Promotes Glioma Progression and Exosome-Mediated Macrophage Immunosuppressive Polarization via Stabilizing IGF2BP3,” Molecular Cancer 21, no. 1 (2022): 16.

[139] X. Zhou, Y. Hong, Y. Liu, et al., “Intervening in hnRNPA2B1-Mediated Exosomal Transfer of Tumor-Suppressive miR-184-3p for Tumor Microenvironment Regulation and Cancer Therapy,” Journal of Nanobiotechnology 21, no. 1 (2023): 422.

[140] S. Li, J. Zhou, S. Wang, et al., “N6-Methyladenosine-Regulated Exosome Biogenesis Orchestrates an Immunosuppressive Pre-Metastatic Niche in Gastric Cancer Peritoneal Metastasis,” Cancer Communications 45, no. 8 (2025): 941–965.

[141] I. Heras-Murillo, I. Adán-Barrientos, M. Galán, S. K. Wculek, and D. Sancho, “Dendritic Cells as Orchestrators of Anticancer Immunity and Immunotherapy,” Nature Reviews Clinical Oncology 21, no. 4 (2024): 257–277.

[142] M. Merad and H. Salmon, “Cancer: A Dendritic-Cell Brake on Antitumour Immunity,” Nature 523, no. 7560 (2015): 294–295.

[143] D. Han, J. Liu, C. Chen, et al., “Anti-Tumour Immunity Controlled Through mRNA m6A Methylation and YTHDF1 in Dendritic Cells,” Nature 566, no. 7743 (2019): 270–274.

[144] C. Wen, L. Wang, A. Piffkó, et al., “YTHDF1 Loss in Dendritic Cells Potentiates Radiation-Induced Antitumor Immunity via STING-Dependent Type I IFN Production,” Journal of Clinical Investigation 134, no. 23 (2024): e181612.

[145] J. A. Myers and J. S. Miller, “Exploring the NK Cell Platform for Cancer Immunotherapy,” Nature Reviews Clinical Oncology 18, no. 2 (2021): 85–100.

[146] N. K. Bjorkstrom, B. Strunz, and H. G. Ljunggren, “Natural Killer Cells in Antiviral Immunity,” Nature Reviews Immunology 22, no. 2 (2022): 112–123.

[147] S. Y. Wu, T. Fu, Y. Z. Jiang, and Z. M. Shao, “Natural Killer Cells in Cancer Biology and Therapy,” Molecular Cancer 19, no. 1 (2020): 120.

[148] L. Cao, E. Morgun, S. Genardi, et al., “METTL14-Dependent m6A Modification Controls iNKT Cell Development and Function,” Cell Reports 40, no. 5 (2022): 111156.

[149] H. Song, J. Song, M. Cheng, et al., “METTL3-Mediated M(6)A RNA Methylation Promotes the Anti-Tumour Immunity of Natural Killer Cells,” Nature Communications 12, no. 1 (2021): 5522.

[150] S. Kim, S. Oh, S. Lee, L. Kong, J. Lee, and T. Kim, “FTO Negatively Regulates the Cytotoxic Activity of Natural Killer Cells,” EMBO Reports 24, no. 4 (2023): e55681.

[151] S. Ma, J. Yan, T. Barr, et al., “The RNA m6A Reader YTHDF2 Controls NK Cell Antitumor and Antiviral Immunity,” Journal of Experimental Medicine 218, no. 8 (2021): e20210279.

[152] X. H. Ding, X. P. Li, F. Chen, H. Wang, and Y. Z. Jiang, “Unlocking T-Cell Plasticity in the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies,” MedComm—Oncology 4, no. 2 (2025): e70023.

[153] W. K. Suh, A. Tafuri, N. N. Berg-Brown, et al., “The Inducible Costimulator Plays the Major Costimulatory Role in Humoral Immune Responses in the Absence of CD28,” Journal of Immunology 172, no. 10 (2004): 5917–5923.

[154] H. B. Li, J. Tong, S. Zhu, et al., “m(6)A mRNA Methylation Controls T Cell Homeostasis by Targeting the IL-7/STAT5/SOCS Pathways,” Nature 548, no. 7667 (2017): 338–342.

[155] Y. Yao, Y. Yang, W. Guo, et al., “METTL3-Dependent M(6)A Modification Programs T Follicular Helper Cell Differentiation,” Nature Communications 12, no. 1 (2021): 1333.

[156] L. Zhang, X. Dou, Z. Zheng, et al., “YTHDF2/m6A/NF-κB Axis Controls Anti-Tumor Immunity by Regulating Intratumoral Tregs,” EMBO Journal 42, no. 15 (2023): e113126.

[157] J. Tong, G. Cao, T. Zhang, et al., “m(6)A mRNA Methylation Sustains Treg Suppressive Functions,” Cell Research 28, no. 2 (2018): 253–256.

[158] H. Chen, Y. Pan, Q. Zhou, et al., “METTL3 Inhibits Antitumor Immunity by Targeting M(6)A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer,” Gastroenterology 163, no. 4 (2022): 891–907.

[159] N. Li, Y. Kang, L. Wang, et al., “ALKBH5 Regulates Anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment,” PNAS 117, no. 33 (2020): 20159–20170.

[160] D. Daassi, K. M. Mahoney, and G. J. Freeman, “The Importance of Exosomal PDL1 in Tumour Immune Evasion,” Nature Reviews Immunology 20, no. 4 (2020): 209–215.

[161] Z. Liu, T. Wang, Y. She, et al., “N(6)-Methyladenosine-Modified circIGF2BP3 Inhibits CD8(+) T-Cell Responses to Facilitate Tumor Immune Evasion by Promoting the Deubiquitination of PD-L1 in Non-Small Cell Lung Cancer,” Molecular Cancer 20, no. 1 (2021): 105.

[162] Z. Hu, G. Chen, Y. Zhao, et al., “Exosome-Derived circCCAR1 Promotes CD8 + T-Cell Dysfunction and Anti-PD1 Resistance in Hepatocellular Carcinoma,” Molecular Cancer 22, no. 1 (2023): 55.

[163] Y. You, D. Wen, L. Zeng, et al., “ALKBH5/MAP3K8 Axis Regulates PD-L1+ Macrophage Infiltration and Promotes Hepatocellular Carcinoma Progression,” International Journal of Biological Sciences 18, no. 13 (2022): 5001–5018.

[164] Z. Ni, P. Sun, J. Zheng, et al., “JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA,” Cancer Research 82, no. 9 (2022): 1789–1802.

[165] H. Liu, X. Zeng, X. Ren, et al., “Targeting Tumour-Intrinsic N(7)-Methylguanosine tRNA Modification Inhibits MDSC Recruitment and Improves Anti-PD-1 Efficacy,” Gut 72, no. 8 (2023): 1555–1567.

[166] C. Cui, H. Zhang, C. Yang, et al., “Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer,” Cancer Research 84, no. 24 (2024): 4199–4213.

[167] X. Chen and E. Song, “Turning Foes to Friends: Targeting Cancer-Associated Fibroblasts,” Nature Reviews Drug Discovery 18, no. 2 (2019): 99–115.

[168] M. Timaner, K. K. Tsai, and Y. Shaked, “The Multifaceted Role of Mesenchymal Stem Cells in Cancer,” Seminars in Cancer Biology 60 (2020): 225–237.

[169] Y. Li, X. Li, M. Deng, C. Ye, Y. Peng, and Y. Lu, “Cancer-Associated Fibroblasts Hinder Lung Squamous Cell Carcinoma Oxidative Stress-Induced Apoptosis via METTL3 Mediated M(6)A Methylation of COL10A1,” Oxidative Medicine and Cellular Longevity 2022 (2022): 4320809.

[170] M. Chen, Q. Zhang, S. Zheng, et al., “Cancer-Associated Fibroblasts Promote Migration and Invasion of Non-Small Cell Lung Cancer Cells via METTL3-Mediated RAC3 M(6)A Modification,” International Journal of Biological Sciences 19, no. 5 (2023): 1616–1632.

[171] Y. Feng, S. Guo, Y. Zhao, et al., “DNA 5mC and RNA M(6)A Modification Successively Facilitates the Initiation and Perpetuation Stages of HSC Activation in Liver Fibrosis Progression,” Cell Death and Differentiation 30, no. 5 (2023): 1211–1220.

[172] Z. Wang, P. Yu, Y. Zou, et al., “METTL1/WDR4-Mediated tRNA M(7)G Modification and mRNA Translation Control Promote Oncogenesis and Doxorubicin Resistance,” Oncogene 42, no. 23 (2023): 1900–1912.

[173] J. Folkman, “Tumor Angiogenesis: Therapeutic Implications,” New England Journal of Medicine 285, no. 21 (1971): 1182–1186..

[174] G. N. Naumov, J. Folkman, and O. Straume, “Tumor Dormancy due to Failure of Angiogenesis: Role of the Microenvironment,” Clinical & Experimental Metastasis 26, no. 1 (2009): 51–60.

[175] R. K. Jain, “Normalizing Tumor Vasculature With Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy,” Nature Medicine 7, no. 9 (2001): 987–989.

[176] W. Chen, H. Bai, Y. Wu, et al., “IDDF2024-ABS-0196 M6A Reader IGF2BP2 Facilitates Angiogenesis and Tumor Progression in Colorectal Cancer via Modulation of CEMIP mRNA Stability and Is a Target for Boosting Antiangiogenic Therapy,” Gut 73, no. 2 (2024): A142.

[177] X. Xu, S. Wu, Y. Zhang, et al., “m6A Modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 Contributes to Angiogenesis of Hepatocellular Carcinoma,” Molecular Carcinogenesis 63, no. 11 (2024): 2174–2189.

[178] K. Chen, W. D. Li, and X. Q. Li, “The Role of m6A in Angiogenesis and Vascular Diseases,” iScience 27, no. 7 (2024): 110082.

[179] X. Liu, H. He, F. Zhang, et al., “m6A Methylated EphA2 and VEGFA Through IGF2BP2/3 Regulation Promotes Vasculogenic Mimicry in Colorectal Cancer via PI3K/AKT and ERK1/2 Signaling,” Cell Death & Disease 13, no. 5 (2022): 483.

[180] M. Ye, J. Chen, P. Yu, et al., “WTAP Activates MAPK Signaling Through m6A Methylation in VEGFA mRNA-Mediated by YTHDC1 to Promote Colorectal Cancer Development,” FASEB Journal 37, no. 8 (2023): e23090.

[181] Q. Wang, C. Chen, Q. Ding, et al., “METTL3-Mediated M(6)A Modification of HDGF mRNA Promotes Gastric Cancer Progression and Has Prognostic Significance,” Gut 69, no. 7 (2020): 1193–1205.

[182] X. Han, M. Wang, Y. L. Zhao, Y. Yang, and Y. G. Yang, “RNA Methylations in Human Cancers,” Seminars in Cancer Biology 75 (2021): 97–115.

[183] S. Panneerdoss, V. K. Eedunuri, P. Yadav, et al., “Cross-Talk Among Writers, Readers, and Erasers of m(6)A Regulates Cancer Growth and Progression,” Science Advances 4, no. 10 (2018): eaar8263.

[184] W. Shen, J. Pu, Z. Zuo, et al., “The RNA Demethylase ALKBH5 Promotes the Progression and Angiogenesis of Lung Cancer by Regulating the Stability of the LncRNA PVT1,” Cancer Cell International 22, no. 1 (2022): 353.

[185] Q. Liao, H. Shi, J. Yang, et al., “FTO Elicits Tumor Neovascularization in Cancer-Associated Fibroblasts Through Eliminating m6A Modifications of Multiple Pro-Angiogenic Factors,” Cancer Letters 592 (2024): 216911.

[186] I. Yamato, M. Sho, K. Shimada, et al., “PCA-1/ALKBH3 Contributes to Pancreatic Cancer by Supporting Apoptotic Resistance and Angiogenesis,” Cancer Research 72, no. 18 (2012): 4829–4839.

[187] Y. Zhao, L. Kong, Z. Pei, et al., “m7G Methyltransferase METTL1 Promotes Post-Ischemic Angiogenesis via Promoting VEGFA mRNA Translation,” Frontiers in Cell and Developmental Biology 9 (2021): 642080.

[188] I. Barbieri and T. Kouzarides, “Role of RNA Modifications in Cancer,” Nature Reviews Cancer 20, no. 6 (2020): 303–322.

[189] C. Shao, F. Yang, S. Miao, et al., “Role of Hypoxia-Induced Exosomes in Tumor Biology,” Molecular Cancer 17, no. 1 (2018): 120.

[190] C. Roma-Rodrigues, R. Mendes, P. V. Baptista, and A. R. Fernandes, “Targeting Tumor Microenvironment for Cancer Therapy,” International Journal of Molecular Sciences 20, no. 4 (2019): 840.

[191] Y. Shi, S. Fan, M. Wu, et al., “YTHDF1 Links Hypoxia Adaptation and Non-Small Cell Lung Cancer Progression,” Nature Communications 10, no. 1 (2019): 4892.

[192] C. Zhang, D. Samanta, H. Lu, et al., “Hypoxia Induces the Breast Cancer Stem Cell Phenotype by HIF-Dependent and ALKBH5-Mediated M(6)A-Demethylation of NANOG mRNA,” PNAS 113, no. 14 (2016): E2047–E2056.

[193] Z. Wang, J. He, D. H. Bach, et al., “Induction of M(6)A Methylation in Adipocyte Exosomal LncRNAs Mediates Myeloma Drug Resistance,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 4.

[194] E. Li, M. Xia, Y. Du, et al., “METTL3 Promotes Homologous Recombination Repair and Modulates Chemotherapeutic Response in Breast Cancer by Regulating the EGF/RAD51 Axis,” eLife 11 (2022): e75231.

[195] H. Li, C. Wang, L. Lan, et al., “METTL3 Promotes Oxaliplatin Resistance of Gastric Cancer CD133+ Stem Cells by Promoting PARP1 mRNA Stability,” Cellular and Molecular Life Sciences 79, no. 3 (2022): 135.

[196] X. Lin, F. Wang, J. Chen, et al., “N(6)-Methyladenosine Modification of CENPK mRNA by ZC3H13 Promotes Cervical Cancer Stemness and Chemoresistance,” Military Medical Research 9, no. 1 (2022): 19.

[197] C. Huang, S. Zhou, C. Zhang, et al., “ZC3H13-Mediated N6-Methyladenosine Modification of PHF10 Is Impaired by Fisetin Which Inhibits the DNA Damage Response in Pancreatic Cancer,” Cancer Letters 530 (2022): 16–28.

[198] Y. Wu, Z. Wang, L. Han, et al., “PRMT5 Regulates RNA m6A Demethylation for Doxorubicin Sensitivity in Breast Cancer,” Molecular Therapy 30, no. 7 (2022): 2603–2617.

[199] Y. Sun, D. Dong, Y. Xia, L. Hao, W. Wang, and C. Zhao, “YTHDF1 Promotes Breast Cancer Cell Growth, DNA Damage Repair and Chemoresistance,” Cell Death & Disease 13, no. 3 (2022): 230.

[200] L. Wei, Y. Bai, L. Na, Y. Sun, C. Zhao, and W. Wang, “E2F3 Induces DNA Damage Repair, Stem-Like Properties and Therapy Resistance in Breast Cancer,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1869, no. 8 (2023): 166816.

[201] C. S. Huang, Y. Q. Zhu, Q. C. Xu, et al., “YTHDF2 Promotes Intrahepatic Cholangiocarcinoma Progression and Desensitises Cisplatin Treatment by Increasing CDKN1B mRNA Degradation,” Clinical and Translational Medicine 12, no. 6 (2022): e848.

[202] C. Zhang, S. Wang, X. Lu, et al., “POP1 Facilitates Proliferation in Triple-Negative Breast Cancer via m6A-Dependent Degradation of CDKN1A mRNA,” Research 7 (2024): 0472.

[203] L. Zhang, Z. Wang, K. Liu, et al., “Targets of Tumor Microenvironment for Potential Drug Development,” MedComm—Oncology 3, no. 1 (2024): e68.

[204] J. C. Moser, K. P. Papadopoulos, J. Rodon Ahnert, Y. Ofir-Rosenfeld, J. B. Holz, and STC15-22101 Study Team., “ Phase 1 Dose Escalation and Cohort Expansion Study Evaluating Safety, PK, PD and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Patients With Advanced Malignancies,” supplement, Journal of Clinical Oncology 42, no. 16 (2024): 2586.

[205] E. Yankova, W. Blackaby, M. Albertella, et al., “Small-Molecule Inhibition of METTL3 as a Strategy Against Myeloid Leukaemia,” Nature 593, no. 7860 (2021): 597–601.

[206] R. Su, L. Dong, Y. Li, et al., “Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion,” Cancer Cell 38, no. 1 (2020): 79–96.e11.

[207] Y. Huang, R. Su, Y. Sheng, et al., “Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia,” Cancer Cell 35, no. 4 (2019): 677–691.e10.

[208] H. Huang, X. Li, J. Luo, et al., “FTO Regulates ELK3-Mediated Metabolic Rewiring and Represents a Unique Therapeutic Target in T Cell Leukemia,” Science Advances 11, no. 22 (2025): eadq3052.

[209] Y. Liu, G. Liang, H. Xu, et al., “Tumors Exploit FTO-Mediated Regulation of Glycolytic Metabolism to Evade Immune Surveillance,” Cell Metabolism 33, no. 6 (2021): 1221–1233.e11.

[210] A. Malacrida, A. Di Domizio, A. Bentivegna, et al., “MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines,” Biology 11, no. 1 (2022): 70.

[211] L. Mahapatra, N. Andruska, C. Mao, J. Le, and D. J. Shapiro, “A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation,” Translational Oncology 10, no. 5 (2017): 818–827.

[212] M. Micaelli, A. Dalle Vedove, and L. Cerofolini, “Small-Molecule Ebselen Binds to YTHDF Proteins Interfering With the Recognition of N6-Methyladenosine-Modified RNAs,” ACS Pharmacology & Translational Science 5, no. 10 (2022): 872–891.

[213] Y. Wang, J. Wang, X. Li, et al., “N1-Methyladenosine Methylation in tRNA Drives Liver Tumourigenesis by Regulating Cholesterol Metabolism,” Nature Communications 12, no. 1 (2021): 6314.

[214] Y. Ofir-Rosenfeld, L. Vasiliauskaitė, C. Saunders, et al., “ STC-15, an Oral Small Molecule Inhibitor of the RNA Methyltransferase METTL3, Inhibits Tumour Growth Through Activation of Anti-Cancer Immune Responses Associated With Increased Interferon Signalling, and Synergises With T Cell Checkpoint Blockade,” supplement, European Journal of Cancer 174 (2022): S123.

[215] N. M. Verrills, H. C. Murray, J. S. Brzozowski, et al., “ Preclinical Evaluation of Bisantrene as Single Agent and in Combination With Decitabine for Acute Myeloid Leukemia,” supplement, Blood 142, no. 1 (2023): 5773.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.